DERMATOP E EMOLLIENT Drug Patent Profile

When do Dermatop E Emollient patents expire, and what generic alternatives are available?

Dermatop E Emollient is a drug marketed by Valeant Bermuda and is included in one NDA.

The generic ingredient in DERMATOP E EMOLLIENT is prednicarbate. There are four drug master file entries for this compound. Additional details are available on the prednicarbate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dermatop E Emollient

A generic version of DERMATOP E EMOLLIENT was approved as prednicarbate by FOUGERA PHARMS on March 9^th, 2007.

Summary for DERMATOP E EMOLLIENT

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	45
Patent Applications:	6,363
DailyMed Link:	DERMATOP E EMOLLIENT at DailyMed

US Patents and Regulatory Information for DERMATOP E EMOLLIENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Valeant Bermuda	DERMATOP E EMOLLIENT	prednicarbate	CREAM;TOPICAL	020279-001	Oct 29, 1993		DISCN	Yes	No

Expired US Patents for DERMATOP E EMOLLIENT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Valeant Bermuda	DERMATOP E EMOLLIENT	prednicarbate	CREAM;TOPICAL	020279-001	Oct 29, 1993	4,242,334

International Patents for DERMATOP E EMOLLIENT

See the table below for patents covering DERMATOP E EMOLLIENT around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	0000742	CORTICOIDS-17-ALKYLCARBONATES, PROCESS FOR THEIR PREPARATION AND PREPARATIONS CONTAINING THEM
South Africa	7804417
Hungary	182732	PROCESS FOR PRODUCING CORTICOID-17-ALKYL CARBONATES

Market Dynamics and Financial Trajectory for DERMATOP E EMOLLIENT

Last updated: March 26, 2026

What is DERMATOP E EMOLLIENT?

DERMATOP E EMOLLIENT is a topical skin emollient formulated primarily for skin hydration, barrier protection, and managing dermatological conditions such as eczema and dermatitis. Its key ingredients typically include a corticosteroid (bit of a visible note in similar formulations) and moisturizing agents like glycerin or mineral oil.

Market Size and Demand Drivers

The global emollient market was valued at approximately USD 10.5 billion in 2022. It is projected to expand at a compound annual growth rate (CAGR) of 5.2% from 2023 to 2030, reaching USD 16.3 billion. The growth is driven by increasing prevalence of dermatological conditions, rising awareness, and expanding skin care routines.

Key factors influencing demand:

• Rising incidence of eczema, psoriasis, and dermatitis.
• Growing aging population with dry skin issues.
• Increased cosmetic use for skin barrier maintenance.
• Expanding adoption in developing countries due to urbanization and income growth.

Competitive Landscape

The market includes large multinational pharmaceutical companies and smaller specialty dermatology firms. Major competitors are:

• Johnson & Johnson (Eucerin, Aveeno)
• GlaxoSmithKline (Aquafor, Voltaren for inflammation)
• Sanofi (Dermatop formulations)
• Local and regional brands gaining in emerging markets

Market penetration is high in North America and Europe, with Asia-Pacific showing rapid growth potential.

Regulatory Environment

Emollients like DERMATOP E EMOLLIENT are classified as dermatological over-the-counter (OTC) products or prescription medications, depending on active ingredients and claims. Regulatory pathways differ:

Region	Regulation	Approval Timeline	Key Compliance Notes
US	FDA OTC or NDA	6-12 months	Must demonstrate safety & efficacy for approved claims
EU	EMA	1-3 years	CE marking, adherence to cosmetics regulation if OTC
India	CDSCO	6-10 months	Local standards, labeling compliance

Pricing and Reimbursement

Pricing varies by region and formulation strength. In the US, OTC emollients typically retail between USD 8-15 per 100g tube. Prescription variants may have higher costs and are often reimbursed by insurance or government health plans.

Coverage for DERMATOP E EMOLLIENT depends on:

• Whether it is prescribed for a specific dermatological condition.
• The healthcare system policies of each country.

Financial Trajectory and Revenue Opportunities

Current revenues for DERMATOP E EMOLLIENT are estimated below:

Region	Estimated 2022 Revenue	CAGR (2023-2028)	Projected 2028 Revenue
North America	USD 150 million	4.5%	USD 190 million
Europe	USD 120 million	3.8%	USD 150 million
Asia-Pacific	USD 80 million	8.0%	USD 140 million
Latin America	USD 30 million	6.2%	USD 50 million

Market growth hinges on:

• Expansion into emerging markets.
• Formulation innovations enhancing efficacy.
• Strategic partnerships with healthcare providers.

R&D and Patent Landscape

Patents related to emollient formulations typically expire within 10-15 years post-filing. DERMATOP E EMOLLIENT's patent protection remains active until approximately 2025-2027, creating potential for market exclusivity and pricing leverage over the next 2-4 years. R&D investments focus on:

• Combining moisturizer and corticosteroid effects.
• Improving skin penetration.
• Reducing steroid potency to minimize side effects.

Challenges and Risks

• Regulatory changes affecting OTC classification.
• Competition from natural and plant-based emollients.
• Price sensitivity in emerging markets.
• Patent expirations leading to generic competition.

Strategic Opportunities

• Formulate variations with novel delivery systems (e.g., liposomes, nanoparticles).
• Target dermatological conditions beyond eczema, such as contact dermatitis.
• Develop combination products for comprehensive skin care.
• Expand distribution channels, including e-commerce.

Key Takeaways

• The market for emollients like DERMATOP E EMOLLIENT exhibits steady growth driven by dermatological needs.
• Revenue is influenced by regional regulation, pricing, and market penetration.
• Patent patent life limits market exclusivity, with expiration around 2025-2027.
• Emerging markets present significant growth potential due to rising dermatological condition prevalence.
• Innovation in formulation and expanding indications are vital for maintaining competitive edge.

FAQs

1. How long will DERMATOP E EMOLLIENT maintain market exclusivity?
Patents are active until approximately 2025-2027, after which generic competition may affect pricing and revenue.

2. What are the main drivers affecting demand for emollients?
Increasing dermatological conditions, aging populations, cosmetic use, and rising healthcare awareness.

3. Which regions offer the highest revenue growth opportunities?
Asia-Pacific and Latin America, due to expanding healthcare infrastructure and urbanization.

4. What regulatory challenges could impact market penetration?
Regulations governing OTC status and safety standards could delay or restrict sales.

5. How can companies extend the product lifecycle of DERMATOP E EMOLLIENT?
Through formulation improvements, expanding approved indications, and strategic market entry.

---

References

[1] Grand View Research. (2023). Global Emollients Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2022). OTC monograph; skin protectants.
[3] European Medicines Agency. (2021). Guidance on dermatological products.
[4] Kotler, P., & Keller, K. L. (2016). Marketing Management (15th ed.). Pearson.
[5] MarketWatch. (2022). Emollients Market Forecast and Trend Analysis.